• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.

作者信息

van Boxtel Wim, Boon Eline, Weijs Willem L J, van den Hoogen Frank J A, Flucke Uta E, van Herpen Carla M L

机构信息

Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 AG Nijmegen, The Netherlands.

Department of Oral and Maxillofacial Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 AG Nijmegen, The Netherlands.

出版信息

Oral Oncol. 2017 Sep;72:198-200. doi: 10.1016/j.oraloncology.2017.06.023. Epub 2017 Jun 30.

DOI:10.1016/j.oraloncology.2017.06.023
PMID:28673692
Abstract
摘要

相似文献

1
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.多西他赛、曲妥珠单抗和帕妥珠单抗联合应用或曲妥珠单抗-恩美曲妥珠单抗治疗转移性涎腺导管癌。
Oral Oncol. 2017 Sep;72:198-200. doi: 10.1016/j.oraloncology.2017.06.023. Epub 2017 Jun 30.
2
Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.多西他赛、曲妥珠单抗和帕妥珠单抗（DTP）作为一线抗 HER2 治疗，阿替利珠单抗联合曲妥珠单抗和美坦新（T-DM1）作为二线治疗复发性或转移性 HER2 阳性唾液腺癌的病例系列。
Oral Oncol. 2022 Feb;125:105703. doi: 10.1016/j.oraloncology.2021.105703. Epub 2022 Jan 4.
3
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.ado曲妥珠单抗（ado-曲妥珠单抗）：一种HER2阳性靶向抗体药物偶联物。
Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31.
4
Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.人表皮生长因子受体 2 高表达唾液腺癌对曲妥珠单抗、帕妥珠单抗和多西他赛的显著反应。
Head Neck. 2018 Dec;40(12):E100-E106. doi: 10.1002/hed.25392. Epub 2018 Nov 26.
5
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.曲妥珠单抗-美坦新偶联物治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者。
Future Oncol. 2013 Jul;9(7):955-7. doi: 10.2217/fon.13.74.
6
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.ado曲妥珠单抗（T-DM1）：一种用于治疗HER2阳性转移性乳腺癌的新型抗体药物偶联物。
J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27.
7
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌。
Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.
8
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.曲妥珠单抗-美坦新偶联物对比医师选择的治疗方案用于治疗既往接受过治疗的人表皮生长因子受体 2（HER2）阳性转移性乳腺癌患者（TH3RESA）：一项随机、开放性、III 期临床试验的最终总生存结果。
Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16.
9
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.曲妥珠单抗-恩杂鲁胺，一种用于治疗HER2阳性转移性乳腺癌的抗体药物偶联物。
Curr Opin Mol Ther. 2010 Jun;12(3):350-60.
10
Trastuzumab emtansine in breast cancer.曲妥珠单抗-恩杂鲁胺用于乳腺癌治疗
Expert Opin Biol Ther. 2013 Apr;13(4):607-14. doi: 10.1517/14712598.2013.778238.

引用本文的文献

1
Complete Response in Salivary Duct Carcinoma Ex Pleomorphic Adenoma With Upfront Combination of Trastuzumab and Chemo-Hormonal Therapy.曲妥珠单抗与化疗-激素疗法 upfront 联合治疗多形性腺瘤恶变的涎腺导管癌的完全缓解
Cureus. 2025 Apr 21;17(4):e82742. doi: 10.7759/cureus.82742. eCollection 2025 Apr.
2
Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma.来那替尼及抗HER2治疗在涎腺导管癌中的作用
Cancer Rep (Hoboken). 2025 Jan;8(1):e70065. doi: 10.1002/cnr2.70065.
3
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
HER2靶向治疗或雄激素剥夺疗法在涎腺导管癌中的生存获益。
Ther Adv Med Oncol. 2022 Sep 6;14:17588359221119538. doi: 10.1177/17588359221119538. eCollection 2022.
4
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.EZH2和H3K27me3表达作为涎腺导管癌患者临床预后预测指标的作用：一项着重于与联合雄激素阻断及HER2靶向治疗相关性的大样本研究
Front Oncol. 2022 Feb 3;11:779882. doi: 10.3389/fonc.2021.779882. eCollection 2021.
5
ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.通过免疫组织化学、荧光原位杂交和靶向外显子组测序评估 67 例唾液腺癌中的 ERBB2 扩增状态。
Mod Pathol. 2022 Jul;35(7):895-902. doi: 10.1038/s41379-021-00999-0. Epub 2021 Dec 28.
6
Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma.转移性腮腺鳞状细胞癌的药物筛选指导下的靶向治疗
Front Oncol. 2021 Sep 16;11:735820. doi: 10.3389/fonc.2021.735820. eCollection 2021.
7
Educational Case: Diagnostic Approach to Salivary Gland Neoplasms.教育案例：唾液腺肿瘤的诊断方法
Acad Pathol. 2021 May 25;8:23742895211015342. doi: 10.1177/23742895211015342. eCollection 2021 Jan-Dec.
8
Molecular patterns in salivary duct carcinoma identify prognostic subgroups.唾液腺癌中的分子模式可识别预后亚组。
Mod Pathol. 2020 Oct;33(10):1896-1909. doi: 10.1038/s41379-020-0576-2. Epub 2020 May 26.
9
Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study.镓-PSMA-HBED-CC PET/CT 成像在腺样囊性癌和唾液腺癌中的应用：一项 2 期影像学研究。
Theranostics. 2020 Jan 12;10(5):2273-2283. doi: 10.7150/thno.38501. eCollection 2020.
10
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.预测唾液腺癌患者雄激素剥夺治疗的临床获益。
Int J Cancer. 2020 Jun 1;146(11):3196-3206. doi: 10.1002/ijc.32795. Epub 2019 Dec 12.